Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Trial details
- Registry ID
- NCT04844749
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Sabizabulin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentNCT04844749 | VERU | Phase 3 | Terminated | 2023-05-04Actual |
| VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on StudyNCT04842747 | VERU | Phase 3 | Completed | 2022-07-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |